

Meeting to commence at 9.30am on Wednesday 15th June 2022 Virtual via Zoom

AGENDA

Enclosure

- 1. Welcome and introduction
- 2. Apologies
- 3. **Declarations of interest**
- 4. Minutes of the previous meeting 1/AWMSG/0622
- 5. Chairman's report
- 6. **AWMSG Work Programme consultation** (for discussion/information) **2**/AWMSG/0622

(to follow)

- 7. **Medicines Optimisation Work Programme** (for discussion/information **3**/AWMSG/0622
- 8. **Review of AWMSG Statements of Advice** (for discussion/information) 4/AWMSG/0622
- 9. **AWMSG 20 Year Anniversary Conference** (verbal update)
- 10. **Best Practice Day 2022** (for discussion/information) 5/AWMSG/0622

To protect commercial confidentiality the following appraisal will be conducted in private and all observers will be asked to leave the meeting

11. Full Submission (PAS)

Bevacizumab (Avastin®) in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix

6/AWMSG/0622 Appendices

The outcome of the appraisal will be uploaded to the AWMSG website after the meeting

Date and time of next meeting: Tuesday 12th July 2022 at 9:30am in Cardiff